FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 342:1824-1826 June 15, 2000 Number 24 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text Purchase this article Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited Related Article by Bennett, C. L. PubMed Citation

In this issue of the Journal, Bennett et al. describe 11 cases of thrombotic thrombocytopenic purpura that occurred in patients during or shortly after they received clopidogrel.¹ The evidence linking clopidogrel to the development of thrombotic thrombocytopenic purpura is strengthened by the finding that the disorder began within 14 days after the initiation of clopidogrel therapy in all but one patient.

Thrombotic thrombocytopenic purpura is known to occur in patients who are treated with ticlopidine, a similar antiplatelet drug. The similarities between ticlopidine and clopidogrel extend beyond their mechanism of action. Both drugs inhibit platelet aggregation in response to adenosine . . . [Full Text of this Article]

References

Related Letters:

Clopidogrel and Thrombotic Thrombocytopenic Purpura
Salliere D., Kassler-Taub K. B., Trontell A. E., Honig P. K., Brooker J. Z., Cheung R. T.F., Goldstein M. R., Bennett C. L., Connors J. M., Moake J. L., Wood A. J.J.
Extract | Full Text  
N Engl J Med 2000; 343:1191-1194, Oct 19, 2000. Correspondence

This article has been cited by other articles:

• Bennett, C. L., Nebeker, J. R., Yarnold, P. R., Tigue, C. C., Dorr, D. A., McKoy, J. M., Edwards, B. J., Hurdle, J. F., West, D. P., Lau, D. T., Angelotta, C., Weitzman, S. A., Belknap, S. M., Djulbegovic, B., Tallman, M. S., Kuzel, T. M., Benson, A. B., Evens, A., Trifilio, S. M., Courtney, D. M., Raisch, D. W. (2007). Evaluation of Serious Adverse Drug Reactions: A Proactive Pharmacovigilance Program (RADAR) vs Safety Activities Conducted by the Food and Drug Administration and Pharmaceutical Manufacturers. Arch Intern Med 167: 1041-1049 [Abstract] [Full Text]  
• Zakarija, A., Bandarenko, N., Pandey, D. K., Auerbach, A., Raisch, D. W., Kim, B., Kwaan, H. C., McKoy, J. M., Schmitt, B. P., Davidson, C. J., Yarnold, P. R., Gorelick, P. B., Bennett, C. L. (2004). Clopidogrel-Associated TTP: An Update of Pharmacovigilance Efforts Conducted by Independent Researchers, Pharmaceutical Suppliers, and the Food and Drug Administration. Stroke 35: 533-537 [Abstract] [Full Text]  
• Lasser, K. E., Allen, P. D., Woolhandler, S. J., Himmelstein, D. U., Wolfe, S. M., Bor, D. H. (2002). Timing of New Black Box Warnings and Withdrawals for Prescription Medications. JAMA 287: 2215-2220 [Abstract] [Full Text]  
• Keane, J., Gershon, S., Wise, R. P., Mirabile-Levens, E., Kasznica, J., Schwieterman, W. D., Siegel, J. N., Braun, M. M. (2001). Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor {alpha}-Neutralizing Agent. NEJM 345: 1098-1104 [Abstract] [Full Text]  
• Schuhlen, H., Kastrati, A., Pache, J.u., Dirschinger, J., Schomig, A. (2001). Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. J Am Coll Cardiol 37: 2066-2073 [Abstract] [Full Text]  
• Salliere, D., Kassler-Taub, K. B., Trontell, A. E., Honig, P. K., Brooker, J. Z., Cheung, R. T.F., Goldstein, M. R., Bennett, C. L., Connors, J. M., Moake, J. L., Wood, A. J.J. (2000). Clopidogrel and Thrombotic Thrombocytopenic Purpura. NEJM 343: 1191-1194 [Full Text]  
• (2000). TTP Associated with Clopidogrel. JWatch General 2000: 1-1 [Full Text]